Search

DexCom Inc

Закрыт

СекторЗдравоохранение

91.02 -1.18

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

90.86

Макс.

92.56

Ключевые показатели

By Trading Economics

Доход

50M

249M

Продажи

117M

1.3B

P/E

Средняя по отрасли

35.083

57.371

Прибыль на акцию

0.7

Рентабельность продаж

19.039

Сотрудники

11,000

EBITDA

52M

389M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+0.97% upside

Дивиденды

By Acuity

Следующий отчет о доходах

29 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

5.2B

33B

Предыдущая цена открытия

92.2

Предыдущая цена закрытия

91.02

DexCom Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

21 авг. 2026 г., 19:36 UTC

Social Media

Dexcom Inc shares are higher as $1.6 million in call options signals bullish investor sentiment. The stock has recovered from earlier session lows.

20 авг. 2026 г., 19:36 UTC

Dexcom Inc shares are higher today, continuing a three-session upward trend. The stock has fluctuated within a narrow range during regular trading hours.

19 авг. 2026 г., 19:41 UTC

Dexcom Inc shares are higher Wednesday, pulling back from an early peak. The stock is trading with unusually high volume and remains above its 20-day moving average.

18 авг. 2026 г., 19:16 UTC

Dexcom Inc shares are higher today, reflecting positive market sentiment despite no specific news. The stock remains above its 20-day moving average.

17 авг. 2026 г., 19:46 UTC

Dexcom Inc's shares are lower today, continuing a decline since Friday's close. No specific news has been identified to explain the price movement.

14 авг. 2026 г., 19:16 UTC

Dexcom Inc shares are lower today, continuing a decline since Thursday's close amid broader market caution following an unexpected drop in U.S. retail sales.

13 авг. 2026 г., 19:26 UTC

Dexcom Inc shares are higher today, despite an earlier pullback. The stock's advance contrasts with a broader market decline since the session's start.

12 авг. 2026 г., 19:36 UTC

Dexcom Inc shares are higher amid broader market optimism following inflation data. The core Consumer Price Index showed a modest increase, aligning with forecasts.

11 авг. 2026 г., 23:26 UTC

Dexcom Inc shares are trading lower in after-market hours. Broader market trends and cautious investor sentiment may be influencing this price movement.

10 авг. 2026 г., 20:02 UTC

Dexcom Inc shares are higher today, continuing an upward trend since Friday. The move occurs amid recent labor market data influencing investor sentiment.

7 авг. 2026 г., 23:46 UTC

Dexcom Inc shares are higher in after-market hours, continuing recent positive momentum. The stock remains well above its 20-day moving average.

5 авг. 2026 г., 19:51 UTC

News

Dexcom shares are declining amid negative sentiment in the insulin sector following Podd's revenue growth forecast cut. Broader economic data also influences cautious market sentiment.

4 авг. 2026 г., 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3 авг. 2026 г., 20:02 UTC

News
Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31 июл. 2026 г., 20:04 UTC

News
Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30 июл. 2026 г., 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29 июл. 2026 г., 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28 июл. 2026 г., 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27 июл. 2026 г., 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24 июл. 2026 г., 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22 июл. 2026 г., 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21 июл. 2026 г., 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 июл. 2026 г., 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Сравнение c конкурентами

Изменение цены

DexCom Inc Прогноз

Целевая цена

By TipRanks

0.97% рост

Прогноз на 12 месяцев

Средняя 93.24 USD  0.97%

Максимум 105 USD

Минимум 82 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для DexCom Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

19 ratings

18

Покупка

1

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat